Last edition
News about
Pfizer Completes Acquisition of Metsera
Pfizer has finalised its acquisition of Metsera, adding a portfolio of differentiated, clinical-stage obesity therapies with the potential to redefine future treatment standards. The deal strengthens and reshapes Pfizer’s internal medicine portfolio, positioning the company to compete more aggressively in therapeutic areas, globally.
Pfizer Cuts Majority of Its BioNTech Stake in Strategic Realignment
After the sale, Pfizer now holds around 1.66 million American Depositary Shares, valued at roughly USD 163 million as of late September 2025.
EirGenix Signs Second Global Licensing Deal With Sandoz for Pertuzumab Biosimilar
EirGenix Inc., a Taiwan-based biopharmaceutical and CDMO company, has signed a second global exclusive licensing agreement with Sandoz AG for the commercialization of its pertuzumab biosimilar EG1206A, developed as an alternative to Roche’s Perjeta.
Merck Poised to Acquire Cidara Therapeutics in Deal Valued Above USD 3.3 Billion
Merck & Co. is reportedly closing in on the acquisition of Cidara Therapeutics, a biotechnology company focused on long-acting antibody treatments for influenza. The deal is expected to value Cidara above its USD 3.3 billion market capitalisation.
Fischer Medical Ventures Appoints Dr. Iype Cherian as Director
Fischer Medical Ventures has appointed globally renowned neurosurgeon and innovator Dr. Iype Cherian as Director, strengthening its leadership as the company advances its next-generation intraoperative MRI technology - DRIS–iMRI Medharanya.
Natural Capsules Posts Stable Q2, but US Tariffs Slow HPMC Expansion
Natural Capsules, one of India’s leading capsule manufacturers, has announced its financial results for the quarter and half year ended September 30, 2025, reporting steady demand but acknowledging multiple external and operational challenges that have impacted growth.
Lupin Launches Risperidone Extended-Release Injectable with 180-day CGT Exclusivity in the US
Risperidone Long-Acting Injectable is Lupin’s first product using its proprietary PrecisionSphere technology developed by its subsidiary Nanomi.
Sun Pharma Presents Two Posters on Utreglutide at ObesityWeek 2025
Sun Pharma presented new clinical data on its investigational GLP-1 agonist, Utreglutide, at ObesityWeek 2025, highlighting meaningful reductions in body weight, waist circumference, and lipid parameters across two studies, with the therapy showing a favourable and class-consistent safety profile.
Biocon Clarifies Media Reports on Possible Biocon Biologics Merger
Biocon has issued a clarification regarding recent media reports suggesting that the company is considering a potential merger of its unlisted subsidiary, Biocon Biologics Ltd. (BBL), along with IPO and share swap options.
Lupin Receives EIR from US FDA for its Aurangabad (CSN) Facility
Lupin has received an Establishment Inspection Report (EIR) from the US FDA for its Aurangabad (CSN) facility, marking the successful closure of a product-specific Pre-Approval Inspection conducted between September 1 and September 5, 2025.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy